Probing Torpedo californica acetylcholinesterase catalytic Gorge with two novel bis-functional galanthamine derivatives

Journal of Medicinal Chemistry

Volumn 53, Issue 2, 2010, Pages 745-751

  Bartolucci, Cecilia ^a   Haller, Lars A ^b   Jordis, Ulrich ^c   Fels, Gregor ^b   Lamba, Doriano ^d  

^a CNR   (Italy)

^b UNIVERSITY OF PADERBORN   (Germany)

^c VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALKALOID; CHOLINESTERASE INHIBITOR; DECAMETHONIUM; DONEPEZIL; GALANTHAMINE DERIVATIVE; N PIPERIDINOPROPYLGALANTHAMINE; N SACCHARINOHEXYLGALANTHAMINE; PIPERIDINE DERIVATIVE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CHOLINERGIC SYSTEM; CHOLINESTERASE INHIBITION; CRYSTAL STRUCTURE; DEMENTIA; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME STRUCTURE; HUMAN; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; TORPEDO CALIFORNICA; X RAY CRYSTALLOGRAPHY;

ACETYLCHOLINESTERASE; ANIMALS; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; GALANTAMINE; MOLECULAR PROBES; PIPERIDINES; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP; TORPEDO;

EID: 77249107098     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901296p     Document Type: Article

References (50)

1. Perry, E. K.; Tomlinson, B. E.; Blessed, G.; Bergman, K.; Gibson, P. H.; Perry, R. H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J. 1978, 25, 1457-1459.
2. Selkoe, D. J. Biochemistry of altered brain proteins in Alzheimer's disease. Annu. Rev. Neurosci. 1989, 12, 463-490.
3. Schrattenholz, A.;Pereira,E.F.; Roth,U.; Weber,K.H.;Albuquerque, E. X.; Maelicke, A. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands. Mol. Pharmacol. 1996, 49, 1-6.
4. Maelicke, A. In Therapeutic Strategies in Dementia; Ritchie, C. W., Ames, D., Masters, C. L., Cummings, J., Eds.; Clinical Publishing: Oxford, 2007; pp 153-172
5. Davis, K. L.; Powchik, P. Tacrine. Lancet 1995, 345, 625-630.
6. Kawakami, Y.; Inoue, A.; Kawai, T.; Wakita, M.; Sugimoto, H.; Hopfinger, A. J. The rational for E2020 as a potent acetylcholinesterase inhibitor. Bioorg. Med. Chem. 1996, 4, 1429-1446.
7. Enz, A.; Boddeke, H.; Gray, J.; Spiegel, R. Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor. Ann. N.Y. Acad. Sci. 1991, 640, 272-275.
8. Marco-Contelles, J.; do Carmo Carreiras, M.; Rodriguez, C.; Villarroya, M.; Garcia, A. G. Synthesis and pharmacology of galantamine. Chem. Rev. 2006, 106, 116-133.
9. Liang, P. H.; Ling-Wei Hsin, L. W; Pong, S. L.; Hsu, C. H.; Cheng, C. Y. Synthesis of galanthamine analogs as acetylcholinesterase inhibitors via intramolecular Heck cyclization. J. Chin. Chem. Soc. 2003, 50, 449-456.
10. Knesl, P.; Yousefi, B. H.; Mereiter, K.; Jordis, U. Synthesis of ( - )-and (+)-8-fluoro-galanthamine. Tetrahedron Lett. 2006, 47, 5701-5703.
11. Vanlaer, S.;DeBorggraeve,W.M.;Voet,A.;Gielens,C.;DeMaeyer, M.; Compernolle, F. Spirocyclic pyridoazepine analogues of galanthamine: synthesis, modeling studies and evaluation as inhibitors of acetylcholinesterase. Eur. J. Org. Chem. 2008, 2571-2581.
12. Jordis, U.; Froehlich, J.; Treu, M.; Hinschall, M.; Czollner, L.; Kaeltz, B.; Welzig, S. New derivative and analogue of galanthamine. European Patent EP 1 181 294 B1, 2001.
13. Herlem, D.; Martin, M. T.; Thal, C.; Guillou, C. Synthesis and structure-activity relationships of open D-ring galanthamine analogues. Bioorg. Med. Chem. Lett. 2003, 13, 2389-2391.
14. Guillou, C.; Mary, A.; Renko, D. Z.; Gras, E.; Thal, C. Potent acetylcholinesterase inhibitors: design, synthesis and structure - activity relationships of alkylene linked bis-galanthamine and galanthamine- galanthaminium salts. Bioorg. Med. Chem. Lett. 2000, 10, 637-639.
15. Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Potent acetylcholinesterase inhibitors: design, synthesis, and structure-activity relationships of bis-interacting ligands in the galanthamine series. Bioorg. Med. Chem. 1998, 6, 1835-1850.
16. Pilger, C.; Bartolucci, C.; Lamba, D.; Tropscha, A.; Fels, G. Accurate prediction of the bound conformation of galanthamine in the active site of Torpedo californica acetylcholinesterase using molecular docking. J. Mol. Graphics Modell. 2001, 19, 288-296.
17. Greenblatt, H. M.; Guillou, C.; Guérard, D.; Argaman, A.; Botti, S.; Badet, B.; Thal, C.; Silman, I.; Sussman, J. L. The complex of a bivalent derivative of galanthamine with Torpedo acetylcholinesterase displays drastic deformation of the active site gorge: implication for structure-based drug design. J. Am. Chem. Soc. 2004, 126, 15405-15411.
18. Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Selective Ndemethylation of galanthamine to norgalanthamine via a non classical Polonovski reaction. Tetrahedron Lett. 1997, 38, 5151-5152.
19. Treu, M.; Hirnschall, M.; Froehlich, J.; Czollner, L.; Kaelz, B.; Kaelz, T.; Kuehnhackl, P.; Jordis, U. Methods for producing norgalanthamine, as well as isomers, salts and hydrates thereof. PCT Int. Appl. WO 2003080623, 2003.
20. Commerford, J. D.; Donahoe, H. B. N-(ω-Bromoalkyl)saccharins and N,N'-undecamethylene disaccharin. J. Org. Chem. 1956, 21, 583-584.
21. Bartolucci, C.; Perola, E.; Pilger, C.; Fels, G.; Lamba, D. Three dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs. Proteins 2001, 42, 182-191.
22. Greenblatt,H. M.; Kryger, G.; Lewis, T. T.; Silman, I.; Sussman, J. L. Structure of acetylcholinesterase complexed with ( - )-galanthamine at 2.3A resolution. FEBS Lett. 1999, 463, 321-326.
23. Mihailova, D.; Yamboliev, I. Pharmacokinetics of galanthamine hydrobromide (Nivalin) following single intravenous and oral administration in rats. Pharmacology 1986, 32, 301-306.
24. Harel, M.; Schalk, I.; Ehret-Sabatier, L.; Bouet, F.; Goeldner, M.; Hirth, C.; Axelsen, P. H.; Silman, I.; Sussmann, J. L. Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9031-9035.
25. Kryger, G.; Silman, I.; Sussmann, J. L. Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs. Structure 1999, 7, 297-307.
26. Bartolucci, C.; Perola, E.; Cellai, L.; Brufani, M.; Lamba, D. "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. Biochemistry 1999, 38, 5714-5719.
27. McMartin, C.; Bohacek, R. S. J. Powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 1997, 11, 333-344.
28. Alisaraie, L.; Haller, L. A.; Fels, G. A QXP-based multistep docking procedure for accurate prediction of protein-ligand complexes. J. Chem. Inf. Model. 2006, 46, 1174-1187.
29. Kone, S.; Galland, N.; Graton, J.; Illien, B.; Laurence, C.; Guillou, C.; Le Questel, J. Y. Structural features of neutral and protonated galanthamine: A crystallographic database and computational investigation. Chem. Phys. 2006, 49, 5051-5058.
30. Xu, Y.; Colletier, J. P.; Weik, M.; Jiang, H.; Moult, J.; Silman, I.; Sussman, J. L. Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray vs molecular dynamics. Biophys. J. 2008, 95, 2500-2511.
31. Xu, Y.; Colletier, J. P.; Jiang, H.; Silman, I.; Sussman, J. L.; Weik, M. Induced-fit or pre-existing equilibriumdynamics? Lessons from protein crystallography andMDsimulations on acetylcholinesterase. Protein Sci. 2008, 17, 601-605.
32. Ravelli, R. B. G.; Raves, M. L.; Ren, Z.; Bourgeois, D.; Roth, M.; Kroon, J.; Silman, I.; Sussman, J. L. Static Laue diffraction studies on acetylcholinesterase. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 1359-1366.
33. Mary, A.; Renko, D. Z.; Guillou, C.; Thal, C. Selective Ndemethylation of galanthamine to norgalanthamine via a nonclassical Polonovski reaction. Tetrahedron Lett. 1997, 38, 5151-5152.
34. Treu, M.; Hirnschall, M.; Froehlich, J.; Czollner, L.; Kaelz, B.; Kaelz, T.; Kuehnhackl, P.; Jordis, U. Methods for producing norgalanthamine, as well as isomers, salts and hydrates thereof. PCT Int. Appl. WO 2003080623, 2003.
35. Commerford, J. D.; Donahoe, H. B. N-(ω-Bromoalkyl)saccharins and N,N'-undecamethylene disaccharin. J. Org. Chem. 1956, 21, 583-584.
36. Sussman, J. L.; Harel, M.; Frolow, F.; Varon, L.; Toker, L.; Futerman, A. H.; Silman, I. Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C. J. Mol. Biol. 1988, 203, 821-823.
37. Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276, 307-326.
38. Collaborative Computational Project No. 4. Acta Crystallogr., Sect D: Biol. Crystallogr., 1994, 50, 760-763.
39. Sussmann, J. L.; Harel, M.; Frolow, F.; Oefner, C.; Goldman, A.; Toker, L.; Silman, I. Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 1991, 253, 872-879.
40. Dvir, H.; Jiang, H. L.; Wong, D. M.; Harel, M.; Chetrit, M.; He, X. C.; Jin, G. Y.; Yu, G. L.; Tang, X. C.; Silman, I.; Bai, D. L.; Sussman, J. L. X-Ray structures of Torpedo californica acetylcholinesterase complexed with (+)-HuperzineAand (-)-Huperzine B: structural evidence for an active site rearrangement. Biochemistry 2002, 41, 10810-10818.
41. Br̈unger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nigels, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921.
42. Read, R. J. Improved Fourier coefficients for maps using phases from partial structures with errors. Acta Crystallogr., Sect. A: Found. Crystallogr. 1986, 42, 140-149.
43. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 110-119.
44. Kleywegt, G. J. Use of non-crystallographic symmetry in protein structure refinement. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1996, 52, 842-857.
45. Wallace, A. C.; Laskowski, R. A.; Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995, 8, 127-134.
46. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC: San Carlos, CA, http://www.pymol.org.
47. Molecular Operating Environment (MOE2008.10); Chemical Computing Group, Inc.: 1010 Sherbrooke St. W, Suite 910 Montreal, Quebec, Canada H3A 2R7.
48. Engh, R. A.; Huber, R. Accurate bond and angle parameters for Xray protein structure refinement. Acta Crystallogr., Sect. A: Found. Crystallogr. 1991, 47, 392-400.
49. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M.PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26, 283-291.
50. Kleywegt, G. J. Validation of protein models from CR coordinates alone. J. Mol. Biol. 1997, 273, 371-376.